News for Arbutus Biopharma Corporation (0SGC.L)

Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon AB-101

Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP

Arbutus Biopharma (ABUS) to present five abstracts at EASL Congress 2025 in Amsterdam. Key findings include the efficacy of Imdusiran and AB-101 in trea

**media[602521]**

Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending

Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially curative

BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with

**media[555746]**

**media[555742]**

WARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation ( ABUS) (”œArbutus” or the ”œCompany”), a clinical-stage biopharmaceut

Chris DeMuth, Jr. shares what's special about Arbutus, Burford Capital, and Cadiz and why an M&A boom is coming.

**media[513454]**

Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon

Whitefort Capital Management, LP (together with its affiliates, ”œWhitefort Capital,” ”œus” or ”œwe”), which is a long-term investor and the third lar

WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation ( ABUS), (”œArbutus” or the ”œCompany”), a clinical-stage biopharmaceut

**media[476552]**

New trial shows promise for chronic hepatitis B treatment

50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial

Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other cohorts asse…